Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients
Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients
Recruiting · NCT05274048 · Registry updated 2026-09-21Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients | Cancer of Gastrointestinal Tract, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, gastric cancer, gastric neoplasm, neoplasm, stomach disorder | Recruiting | Phase 1 | 2026-09-21 | NCT05274048 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Fox Chase Cancer Center | 58 |
| National Comprehensive Cancer Network | 27 |
| Puma Biotechnology, Inc. | 11 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Fox Chase Cancer Center | Philadelphia | United States | 259 |
| Roswell Park Comprehensive Cancer Center | Buffalo | United States | 63 |
| Stanford Cancer Center | Palo Alto | United States | 18 |